TABLE 1.

Some ongoing clinical trials utilizing various gene panels/tests.

Gene panel/test	Number of genes	Utility	Ongoing (recruiting) clinical trials
PAM-50 (Pro-Signa) Wallden et al. (2015)	50	Prediction and risk assessment	19- including NCT04344496, NCT03749421, NCT04759248, NCT03769415, NCT02889874, NCT01560663, NCT04578106, NCT03904173, NCT02448420, NCT04610528, NCT04759248
MammaPrint® Wittner et al. (2008)	70	Prediction and prognosis	4- NCT05474391, NCT03053193, NCT03900637, NCT04129216
EndoPredict® Filipits et al. (2011)	12	Prognosis	4- NCT04246606, NCT03503799, NCT03969121, NCT01805271
BluePrint® Mittempergher et al. (2020)	80	Diagnosis	4- NCT03053193, NCT04129216, NCT05252416, NCT03900637
Oncotype DX® Paik et al. (2004)	21	Prediction	11- NCT04852887, NCT03495011, NCT02476786, NCT01560663, NCT03212170, NCT03961880, NCT03703492, NCT02095184, NCT04797299, NCT02993159, NCT03220893
Invitae https://www.invitae.com/en/providers/test-catalog/test-01102	8 different kits with up to 84 genes	Prediction, risk assessment	2- NCT04354675, NCT04985266